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Background/aim: This study aimed to evaluate the clinical efficacy of radiofrequency ablation (RFA) and cryotherapy and to scrutinize
the therapeutic success of the RENAL (radius, exophytic/endophytic, nearness to collecting system, anterior/posterior, and location)
nephrometry score in terms of possible complications and the predictive status of oncological results.
Materials and methods: Forty-five patients with biopsy-proven renal cell carcinomas (32 males, 13 females) treated with RFA and
cryotherapy were included. Patients were 22–90 years old (average: 59.2 years). Statistical analyses were performed using SPSS for
Windows.
Results: A total of 79 lesions with dimensions varying between 0.9 and 4.5 cm (average: 2.2 cm) were ablated. Complete ablation
was achieved for 72 (91.1%) lesions. Six repeat RFA sessions were applied for 4 (5%) lesions with residue/recurrence. The average
RENAL nephrometry scores of lesions that underwent complete ablation and those that developed residue/recurrence were 6.3 and 7.7,
respectively. The average recurrence-free survival time was 34.8 months (range: 3–55 months), while it was 44.6 months (range: 6–55
months) for cryotherapy and 28.6 months (range: 3–50 months) for RFA.
Conclusions: Ablative therapies are minimally invasive and effective methods for treating small renal tumors. RENAL nephrometry
scoring is a valuable system for standardizing renal tumors and evaluating the success of ablative therapies, possible complications, and
oncological results.
Key words: Radiofrequency ablation, cryotherapy, RENAL nephrometry score

1. Introduction
As the common use of ultrasonography (US) and crosssectional imaging methods such as computed tomography
(CT) and magnetic resonance imaging (MRI) has
intensified, it has become increasingly common to identify
small renal masses incidentally [1]. Recent developments
in medicine over the last few decades have increased the
use of surgical and radiological interventions. Due to the
high rate of survival in patients with localized renal cell
tumors, minimally invasive ablative treatment methods
are of interest as potential therapeutic methods. The most
popular methods are radiofrequency ablation (RFA) and
cryotherapy [2,3].
Ablative therapies, in addition to treating renal masses,
including liver, lung, bone, and soft tissue lesions, have
a wide range of clinical use with increasing number of
indications [4].

In RFA, the target lesion is ablated with coagulation
necrosis using heat generated from high-frequency
alternating current obtained by uninsulated electrode tips
[5,6].
In cryotherapy, during the sudden freezing process,
secondary oxidative phosphorylation of ice crystals,
cytotoxic oxygen radicals, and finally development of
cellular hypoxia destroy the cellular membrane. Necrosis
and irreversible destruction that occur due to repetitive
freeze-thaw cycles provide the eradication of the tumor
[7].
Local ablative therapeutic methods are repeatable and
easily applicable. Associated morbidity and mortality rates
are lower and the cost of treatment is reduced compared
to other surgical therapies. Moreover, these methods can
be synchronously monitored, and if necessary used in
combination with other therapeutic methods to increase
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treatment efficacy [3,8]. The main advantage of these
methods is better preservation of renal parenchymal
volume [9].
The application of quantitative metrics to renal mass
ablation has generally been successful to date [10–12].
Therefore, in the present study we used the RENAL
(radius, exophytic/endophytic, nearness to collecting
system, anterior/posterior, and location) nephrometry
scoring system for this purpose. We evaluated the shortto mid-term clinical efficacy of RFA and cryotherapy for
the treatment of small renal tumors among selected cases
and scrutinized the therapeutic success of the RENAL
nephrometry score in terms of possible complications and
predictive status of oncological results.
2. Materials and methods
A total of 45 patients (32 males and 13 females) were
referred to our clinic for ablative therapy. Mean ± SD
patient age was 59.2 ± 15.7 (22–90) years. After the
Institutional Review Board’s approval, informed consent
was obtained from all patients. The study was approved
by the Ethics Committee of the Gazi University Faculty of
Medicine (Date: 15/06/2011, Decision number: 244).
The main indication for ablative therapies in our series
was comorbidity, including advanced age, hypertension,
diabetes mellitus, and some other malignancies. Other
indications were solitary kidney, patient preference,
hereditary tumor, chronic renal failure, and previous renal
surgery.
Patients with a platelet count below 50,000/mm3 and
INR value above 1.25 were excluded from the study.
At the planning stage, the appropriate ablative
treatment method was determined with the use of US and
CT/MRI, and tumors were evaluated based on number
and dimension of lesions, as well as their localization,
accessibility, and proper administration of injection entry.
The RENAL nephrometry scoring process developed by
Kutikov and Uzzo [10] was used for objective assessment.
The score consists of evaluations of the following tumor
features: radius (at the maximal diameter), exophytic/
endophytic properties, nearness of its deepest portion
to the collecting system or sinus, anterior/posterior
descriptor, and location relative to polar line. The suffix
‘x’ is used for an unknown anterior/posterior designation,
while ‘h’ is used to designate a hilar tumor location
(abutting the main renal artery or vein). All components
except for the anterior descriptor are scored on a 1-, 2-, or
3-point scale.
All patients underwent biopsy just before the ablation
procedure. In 4 patients who were followed up with von
Hippel–Lindau disease with multiple lesions, biopsy was
applied to a single lesion, with the largest lesion being
selected.
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Percutaneous procedures were performed under
the guidance of US and/or CT, while intraoperative
procedures were performed with the guidance of US only.
Similar to the standards specified by Clark et al., in
our study the primary approach in exophytic lesions was
percutaneous therapy. An intraoperative approach was
preferred in patients with multiple lesions, and especially
for anterior and centrally located lesions [13].
We chose primarily cryotherapy and a laparoscopic
approach in some patients to avoid more parenchymal
damage in the lesions located in the anterior of the
kidney. Cryotherapy was the first treatment method
to be preferred by using the cryoresistant feature of the
collecting system in centralized lesions [3,14].
RFA was the first choice for solid and exophytic lesions.
In addition to the convenience of approach in posterior
or lateral lesions, another advantage of RFA is its easy
applicability with one probe instead of a large number of
probes as in cryotherapy.
During RFA, a 15-cm-long, 14-gauge RITA Starburst
Talon thermal ablation electrode was used, in addition
to a RITA model 1500X radiofrequency generator (RITA
Medical Systems/Angiodynamics Inc., Latham, NY,
USA) (Figures 1a–1c). Before starting the RFA process
in 8 (17.7%) patients, in whom 8 (10.1%) lesions were
located adjacent to solid organs, a 5% dextrose solution
was injected into the adjacent kidney using an 18-G Chiba
hydro-dissection needle to prevent organ damage. The
Precise Cryoablation System and 4–6 Iceseed 17-gauge
cryoablation needles (Galil Medical Company, Yoknaem,
Israel) were used in the cryoablation process. A 10-min
freeze-thaw cycle was applied twice after an appropriate
number of probes (selected according to the dimensions
of the lesion) were inserted at intervals of 1–2 cm (Figures
2a–2c).
One month after ablation, patients underwent
dynamic contrast-enhanced CT (LightSpeed CT;
GE Medical Systems, USA) or dynamic kidney MRI
(Magnetom Verio; Siemens, Erlangen, Germany) and
diffusion MRI studies. MRI was preferred as a follow-up
imaging modality according to conditions such as patient
preference, solitary kidney, and presence of impaired
renal function tests. After months 1, 3, 6, and 12, control
evaluations were obtained and then patients were followed
at 1-year intervals.
Contrast retention in the initial follow-up imaging
demonstrated a “residual tumor” in the ablated area.
During the course of follow-up imaging, the appearance
of new tumor foci at the ablative margin after local
eradication was defined as “recurrence” [15].
All data were analyzed using SPSS 15.0 for Windows
(SPSS Inc., Chicago, IL, USA).
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Figure 1. a) Fifty-one-year-old woman with 2.5-cm biopsy-proven renal cell carcinoma marked with green dots. RENAL nephrometry
score calculated as 6. b) CT image obtained with patient in prone position at RFA shows needle electrodes in tumor marked with green
dots. c) CT image obtained with IV contrast material shows mass is no longer enhanced after 3 years (green arrow).

3. Results
A total of 79 renal tumors in 45 patients were ablated. Mean
lesion diameter was 2.2 (0.9–4.5) cm. Median follow-up
was 18.5 (3–55) months (min–max). Tumor and ablation
characteristics are presented in Table 1.
The distribution of lesions according to RENAL
nephrometry score for complete ablation and residue/
recurrence are presented in Table 2. The anterior/posterior
parameter was not found to be significant in terms of

outcomes. The initial average RENAL nephrometry score
was 6.3 for completely treated tumors and 7.7 for tumors
with residue/recurrence. The relationship between each
group was significant (P < 0.016).
The only major complication was pelvicalyceal
system damage during RFA session in one patient,
whose lesion was centrally located and whose RENAL
nephrometry score was 9. The complication was repaired
by a double J and drainage catheter in the Department
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Figure 2. a) Seventy-year-old man with 4-cm biopsy-proven clear cell renal cell carcinoma (green arrow). RENAL nephrometry score
calculated as 5. b) CT image obtained with patient in prone position shows cryoprobes in tumor. c) CT follow-up at 3 years demonstrates
no evidence of tumor enhancement (green arrow).

of Interventional Radiology. Minor complications were
treated conservatively. All complications, according to
ablation procedure and RENAL nephrometry scores, are
listed in Table 3.
As a superiority of ablative therapies to surgical
methods, no significant difference was found between preand postablation in terms of the creatine levels for either
ablation technique (P > 0.05).
The average recurrence-free survival (RFS) was 34.8
months, and RFS decreased with the size and number of
lesions. In addition, while RFS was higher for exophytic
lesions, it was quite low for parenchymal lesions and
especially those with central location. The differences
between exophytic, parenchymal, and centrally localized
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lesion groups were statistically significant (P < 0.001). The
effects of risk factors on RFS are listed in Table 4.
Patients treated with cryotherapy had higher survival
rates than those treated with RFA. In the statistical study
comparing multiple variables, the least effective factor on
the RFS rate was ablation method; therefore, no subgroup
analysis was performed statistically at this point for
RENAL nephrometry score. The most notable risk factors
for residue/recurrence were lesion size and location.
4. Discussion
Clinically, quite successful oncological results are obtained
by nephron-protective surgeries for the treatment of
tumors during the T1a stage [16,17]. The use of ablative
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Table 1. Renal tumor and ablation characteristics.
All ablations

Cryoablation

RFA

No. of renal tumors

79

15

64

Mean ± SD max diameter (cm)

2.2 ± 0.8

2.7 ± 0.8

1.7 ± 0.7

Percutaneous session

35

11

24

Intraoperative session

41

4

37

Laparoscopic session

3

-

3

Recurrence-free survival time (months)

34.8 (3–55)

44.6 (6–55)

28.6 (3–50)

Mean ± SD RENAL score

6.41 ± 1.7

6.40 ± 1.7

6.42 ± 1.7

Low (4–6)

46 (58.2)

8 (53.3)

38 (59.4)

Moderate (7–9)

29 (36.7)

7 (46.7)

22 (34.4)

High (10–12)

4 (5.1)

-

4 (6.2)

RENAL score tumor complexity (%)

Table 2. Complete ablation and residue/recurrence relationship with RENAL nephrometry score.
Complete ablation

Residue/recurrence

No. of renal tumors

72

7

Mean ± SD max diameter (cm)

1.8 ± 0.8

2.2 ± 0.8

Mean ± SD RENAL score

6.3 ± 1.6

7.7 ± 2.2

(R)adius

1.0 ± 0.1

1.0 ± 0.1

(E)xophytic/endophytic

2.0 ± 0.7

2.2 ± 0.9

(N)earness

1.6 ± 0.7

2.5± 0.7

(L)ocation

1.7 ± 0.8

1.8 ± 0.8

Anterior

24 (33.4)

2 (28.6)

Posterior

32 (44.4)

5 (71.4)

No designation

16 (22.2)

-

Low (4–6)

Moderate (7–9)

High (10–12)

43 (54.4)

26 (33)

3 (3.8)

2 (2.5)

3 (3.8)

2 (2.5)

No. of anterior/posterior placements (%)

RENAL score tumor complexity (%)
Complete ablation
Residue/recurrence

methods is gradually increasing because these methods
are less invasive and are associated with low complication
rates. Hence, there is a need to develop a standardized
method of anticipating complications and deciding on
appropriate therapy. In this study, we used the RENAL
nephrometry scoring system to prospectively evaluate RFA
and cryotherapy in selected cases of renal cell carcinoma
in terms of oncologic outcomes.
The RENAL nephrometry score is based on anatomical
markers of the kidneys, as well as the locations and sizes
of tumors [10,18,19]. The study with the largest patient

series for the RENAL nephrometry scoring system was
published by Schmit et al. [20]. An increase in the score is
linked to an increase in recurrence and complication rate
[11,21,22]. In our study, scores were higher in patients with
residue/recurrence than those who underwent complete
ablation. Furthermore, they were higher in patients
who developed complications. However, no significant
relationship was found between the nephrometry scores of
lesions treated via RFA and cryotherapy. Accordingly, we
assert that nephrometry scores can be considered a guide
for surgeons and interventional radiologists in predicting
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Table 3. Complications.
RFA

Cryotherapy

1 (2.2) – 9

-

Major complications
Pelvicaliceal system damage, n (%) – RENAL nephrometry score
Minor complications
Early impaired renal function tests, n (%) – RENAL nephrometry score

1 (2.2) – 8

-

Subcapsular hematoma, n (%) – RENAL nephrometry score

1 (2.2) – 6

-

Perirenal hematoma, n (%) – RENAL nephrometry score

2 (4.5) – 1st: 7
2nd: 6

1 (2.2) – 8

Skin burn, n (%) – RENAL nephrometry score

-

1 (2.2) – 7

Total, n (%)

5 (11.1)

2 (4.5)

Table 4. The effect of risk factors on recurrence-free survival by
single-variable Kaplan-Meier survival analysis.
RFS time,
mean (95% CI*)

P-value

Single

48.1 (42.6–53.7)

0.123

≥2

17.4 (10.0–24.7)

Lesion number

Lesion size
<3 cm

47.7 (40.9–54.6)

≥3 cm

37.4 (21.2–53.6)

0.140

Lesion localization
Exophytic

50.8 (45.3–56.3)

Parenchymal

37.1 (29.6–44.6)

Central

10.5 (0.0–21.9)

0.001

Ablation method
Cryotherapy

44.6 (34.0–55.1)

RFA

28.6 (23.6–33.5)

0.840

*CI: Confidence interval.

the success of the preferred therapy but not for the type of
ablation. At this point, studies to compare moderate-score
and especially high-score lesions in terms of ablative and
surgical treatment approaches may be useful in the future.
A previous study reported RFS rates of 87% and 90.6%
and complication rates of 6% and 4.9% for RFA and
cryotherapy, respectively [23]. It is generally accepted that
the residue/recurrence and complication rates of RFA are
higher than those of cryotherapy. Our results support these
findings, as RFS was lower for lesions ablated with RFA
than those treated with cryotherapy. The efficacy of RFA
may decrease due to “heat-loss effect” in lesions located
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closer to the hilus and adjacent to vascular structures wider
than 1 cm. Owing to the cryoresistance of the collecting
duct system in these patients, cryotherapy should be the
preferred ablation method [14,24].
A number of factors affect the survival rate in patients
who receive ablative treatment and the most important
prognostic factor is considered to be the size of the lesion
[25,26]. In addition, tumor location is an important factor
that may influence the success of ablation therapy [27,28].
We also observed that complications developed mostly
in centrally and substantially parenchymal localized
lesions. It was noted that these lesions were in the moderate
or high risk group according to the RENAL nephrometry
score.
Our study had some limitations. Fewer lesions were
treated with cryotherapy than with RFA. Moreover, the
presence of patients who had an excessive number of
tumors related to hereditary renal disease and therefore
had residue/recurrence in the RFA group led to
heterogeneity and made statistical analyses of this group
more complicated. In addition, patients may have been
followed after treatment at other institutions, limiting the
accuracy of data regarding recurrences after discharge.
In conclusion, for the management of renal masses,
nonsurgical minimally invasive modalities such as RFA and
cryotherapy are effective and safe alternatives to surgery
in experienced hands. The RENAL nephrometry scoring
system allows standardized evaluation of renal masses and
the success of ablative therapies. Possible complications
and oncological results can also be anticipated with this
system. The number of studies comparing the efficacy
of renal nephrometry scoring in RFA and cryoablation
procedures in the literature is limited. It is emphasized
that RENAL nephrometry scoring predicts the success
of the preferred treatment procedure, but not the type of
ablation.
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